• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Overexpression of Long Non-Coding RNA TUG1 Promotes Colon Cancer Progression.
CONCLUSIONS LncRNA TUG1 may serve as a potential oncogene for colon cancer. Overexpressed TUG1 may contribute to promoting cell proliferation and migration in colon cancer cells. PMID: 27634385 [PubMed - in process]
Source: Medical Science Monitor - September 19, 2016 Category: Research Tags: Med Sci Monit Source Type: research

Resveratrol Treatment Inhibits Proliferation of and Induces Apoptosis in Human Colon Cancer Cells.
CONCLUSIONS These findings suggest that resveratrol treatment can be a promising strategy for the treatment of colon cancer. PMID: 27040803 [PubMed - in process]
Source: Medical Science Monitor - April 5, 2016 Category: Research Tags: Med Sci Monit Source Type: research

LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner
Liver receptor homologue 1 (LRH-1) is an orphan nuclear receptor that has been implicated in the progression of breast, pancreatic and colorectal cancer (CRC). To determine mechanisms underlying growth promotion by LRH-1 in CRC, we undertook global expression profiling following siRNA-mediated LRH-1 knockdown in HCT116 cells, which require LRH-1 for growth and in HT29 cells, in which LRH-1 does not regulate growth. Interestingly, expression of the cell cycle inhibitor p21 (CDKN1A) was regulated by LRH-1 in HCT116 cells. p21 regulation was not observed in HT29 cells, where p53 is mutated. p53 dependence for the regulation o...
Source: Nucleic Acids Research - January 29, 2016 Category: Research Authors: Kramer, H. B., Lai, C.-F., Patel, H., Periyasamy, M., Lin, M.-L., Feller, S. M., Fuller-Pace, F. V., Meek, D. W., Ali, S., Buluwela, L. Tags: Gene regulation, Chromatin and Epigenetics Source Type: research

Method for Predicting and Detecting Tumor Metastasis
Detecting cancer prior to metastasis greatly increases the efficacy of treatment and the chances of patient survival. Although numerous biomarkers have been reported to identify aggressive tumor types and predict prognosis, each biomarker is specific for a particular type of cancer, and no universal marker that can predict metastasis in a number of cancers have been identified. In addition, due to a lack of reliability, several markers are typically required to determine the prognosis and course of therapy. The inventors discovered a novel CPE splice variant designated CPE-deltaN and found its expression levels increase ac...
Source: NIH OTT Licensing Opportunities - January 5, 2009 Category: Research Authors: admin Source Type: research

Pages: 1  2